Quick Takeaways: Why It Matters? Piclidenoson’s Phase 2 enrollment milestone, fully funded by Vetbiolix, moves this A3 adenosine receptor agonist closer to potential registration as a chronic oral osteoarthritis option in dogs, with LOAD, VAS, and ...
Quick Takeaways: Why It Matters? ALA-1000’s data support a true once-monthly, long-acting analgesic option, which could meaningfully shift osteoarthritis pain management away from daily oral medications in suitable dogs. If approved, the combination of dura...
